The influence of CGS 16949A on peripheral aromatisation in breast cancer patients
Per Eystein Lønning(Haukeland University Hospital), Mitch Dowsett(Institute of Cancer Research), Alison Jones(Roche (Switzerland)), Ben P. Haynes(Institute of Cancer Research), TJ Powles(Institute of Cancer Research), S. Jacobs(Institute of Cancer Research)
Cited by 80
Related Papers
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
|Journal of Clinical Oncology|2009|850
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
|BMC Cancer|2010|755
Mechanisms of tamoxifen resistance
|Endocrine Related Cancer|2004|652